COVID-19 may trigger or worsen refractory, or difficult-to-treat, thrombotic thrombocytopenic purpura (TTP) during the first months of pregnancy, requiring early diagnosis and aggressive treatment…
News
Patients with immune thrombocytopenia (ITP) who test positive for antinuclear antibodies (ANA), which mistakenly target the nucleus of cells, are at higher risk of…
Excessive bleeding from a common skin abnormality was the first indication of von Willebrand disease (VWD) in a 1-year-old girl, highlighting the importance of…
The preventive treatment Adzynma (recombinant human ADAMTS13) is safe and effective at reducing disease relapses for people with congenital thrombotic thrombocytopenic purpura (TTP), and…
Combining low-dose eltrombopag with reduced-dose prednisone may be an effective approach for controlling immune thrombocytopenia (ITP) while minimizing the risk of medication side effects,…
Although more people with von Willebrand disease (VWD) have given birth over the past two decades, the rates of certain complications, such as prebirth…
A combination of blood biomarkers can help predict the short-term risk of death for people admitted to the hospital with thrombotic thrombocytopenic purpura (TTP),…
People with immune thrombocytopenia (ITP) who have had their spleens surgically removed may face an increased risk of clotting problems from ITP treatments…
Adding Cyklokapron (tranexamic acid) to Vonvendi (recombinant von Willebrand factor) does not appear to reduce blood loss following childbirth for women with von Willebrand…
Levels of anti-ADAMTS13 antibodies measured after therapeutic plasma exchange (TPE) are associated with the time it takes to achieve normalization of ADAMTS13 activity in people…
